News & Events

OpSens Appoints Brad Davis as New Chief Commercial Officer Davis to lead global commercialization as OpSens pursues transformational growth Quebec City, Quebec, February 9, 2022 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that Brad Davis will assume…

Read more

OPSENS Named to 2022 OTCQX Best 50   Quebec City, Quebec, January 24, 2022 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, is pleased to announce it has been named to the 2022 OTCQX® Best 50, a ranking of top…

Read more

OpSens Announces First Quarter Fiscal 2022 Financial Results Conference call on the results today at 11 a.m. ET Quebec City, Quebec, January 13, 2022 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today reported its results for the first quarter…

Read more

OPSENS TO HOST FIRST QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY, JANUARY 13, 2022  Conference call to be conducted at 11:00 am ET Quebec City, Quebec, January 6, 2022 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology,…

Read more

OpSens Announces 510(K) Submission to U.S. FDA for New Guidewire for the TAVR Procedure Quebec City, Quebec, December 13, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it has filed a 510(k) submission with the U.S….

Read more

OPSENS TO PRESENT AT THE LYTHAM PARTNERS WINTER 2021 INVESTOR CONFERENCE Presentation at 11 AM (ET), Monday December 13, 2021   Quebec, Quebec, December 7, 2021 – OpSens inc. («OpSens» or the «Company») (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, announced today that it will be…

Read more

OpSens Announces Fourth Quarter And Fiscal Year 2021 Financial Results Conference call on the results today at 11 a.m. ET Quebec City, Quebec, November 23, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today reported its results for the…

Read more

OpSens Successfully Completes 20-Patient In-Human Clinical Study for TAVR Procedure TAVR market outlook for procedural growth remains highly attractive globally Quebec City, Quebec, November 23, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary technology, is pleased to announce the successful treatment…

Read more

OpSens to Host Fourth Quarter Fiscal Year 2021 Financial Results Conference Call and Year-End Update on Tuesday, November 23, 2021 Conference call to be conducted at 11:00 am ET Quebec City, Quebec, November 17, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based…

Read more

OpSens Will Participate at Stifel 2021 Virtual Healthcare Conference and Canaccord Genuity  MedTech & Diagnostics Forum    Quebec City, Quebec, November 10, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF),  a medical device cardiology-focused company commercializing a  second-generation fiber optic pressure guidewire to diagnose and treat coronary artery disease, announced today that Louis…

Read more